Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen E Gomez

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Vaccine|December 25, 2010
Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progressionMagdalena Krupa, Marta Canamero, Carmen E Gomez, et al.
Plos One|October 15, 2011
A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virusAlan G Goodman, Paul P Heinen, Susana Guerra, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 3, 2010
Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeysAndrew B Wilks, Elizabeth C Christian, Michael S Seaman, et al.
Plos Pathogens|June 23, 2009
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasomeJulie Delaloye, Thierry Roger, Quynh-Giao Steiner-Tardivel, et al.
Journal of Virology|January 23, 2015
Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteinsJulie Delaloye, Abdelali Filali-Mouhim, Mark J Cameron, et al.
Plos One|November 19, 2011
Improved NYVAC-based vaccine vectorsKaren V Kibler, Carmen E Gomez, Beatriz Perdiguero, et al.
Plos One|September 28, 2017
Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-BMiriam Rosás-Umbert, Beatriz Mothe, Marc Noguera-Julian, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2011
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primatesBarbara J Flynn, Kathrin Kastenmüller, Ulrike Wille-Reece, et al.
Frontiers in Immunology|December 24, 2019
The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1Suresh C Raman, Ernesto Mejías-Pérez, Carmen E Gomez, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2008
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenicMax Corbett, Willy M Bogers, Jonathan L Heeney, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Vaccine|December 25, 2010
Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progressionMagdalena Krupa, Marta Canamero, Carmen E Gomez, et al.
Plos One|October 15, 2011
A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virusAlan G Goodman, Paul P Heinen, Susana Guerra, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 3, 2010
Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeysAndrew B Wilks, Elizabeth C Christian, Michael S Seaman, et al.
Plos Pathogens|June 23, 2009
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasomeJulie Delaloye, Thierry Roger, Quynh-Giao Steiner-Tardivel, et al.
Journal of Virology|January 23, 2015
Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteinsJulie Delaloye, Abdelali Filali-Mouhim, Mark J Cameron, et al.
Plos One|November 19, 2011
Improved NYVAC-based vaccine vectorsKaren V Kibler, Carmen E Gomez, Beatriz Perdiguero, et al.
Plos One|September 28, 2017
Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-BMiriam Rosás-Umbert, Beatriz Mothe, Marc Noguera-Julian, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2011
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primatesBarbara J Flynn, Kathrin Kastenmüller, Ulrike Wille-Reece, et al.
Frontiers in Immunology|December 24, 2019
The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1Suresh C Raman, Ernesto Mejías-Pérez, Carmen E Gomez, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2008
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenicMax Corbett, Willy M Bogers, Jonathan L Heeney, et al.
Pageof 2